

Date: 28/03/2022

FREEDOM OF INFORMATION REQUEST - Ref: FOI/016107 – Breast cancer

Between 01/12/2021 and 28/02/2022, the following number of breast cancer patients were issued with the following drugs

- a) Anthracycline (eg doxorubicin) as single agent - 5
- b) Atezolizumab + nab-paclitaxel or paclitaxel - 0
- c) Capecitabine as a single agent - 6
- d) Eribulin as a single agent or in combination - 1
- e) PARP inhibitor (eg Olaparib) - 0
- f) Pembrolizumab + chemotherapy - 0
- g) Platinum (eg carboplatin, cisplatin) as a single agent - 0
- h) Taxane (eg docetaxel, paclitaxel, nab-paclitaxel) as a single agent - 21
- i) Taxane + Anthracycline based combinations - 0
- j) Vinorelbine as a single agent - 0
- k) Other active systemic anti-cancer therapy - 10